Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - G1 Therapeutics, Inc. | gthx-ex322_406.htm |
| EX-31.2 - EX-31.2 - G1 Therapeutics, Inc. | gthx-ex312_408.htm |
| EX-31.1 - EX-31.1 - G1 Therapeutics, Inc. | gthx-ex311_407.htm |
| EX-23.1 - EX-23.1 - G1 Therapeutics, Inc. | gthx-ex231_479.htm |
| EX-10.7 - EX-10.7 - G1 Therapeutics, Inc. | gthx-ex107_432.htm |
| EX-4.2 - EX-4.2 - G1 Therapeutics, Inc. | gthx-ex42_6.htm |
| 10-K - GTHX 10-K 2020 - G1 Therapeutics, Inc. | gthx-10k_20201231.htm |
Exhibit 32.1
CERTIFICATION UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of G1 Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report for the year ended December 31, 2020 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: February 24, 2021 |
|
/s/ John E. Bailey, Jr. |
|
|
|
John E. Bailey, Jr. |
|
|
|
President and Chief Executive Officer |
|
|
|
(Principal Executive Officer) |